NovaRelief Pro took three years from concept to market. The journey began with identifying limitations in existing analgesic delivery mechanisms. Our team developed NovaBond™ technology—a nano-delivery system that enables targeted release at inflammation sites. Phase III clinical trials across 12 centres demonstrated 94% patient satisfaction and a 60% faster onset of action compared to conventional formulations. This article walks you through each stage of the development process.
research